News Headlines Article

Government health programs pay billions for Gilead’s hepatitis C drug as company tax rate drops
San Francisco Business Times

While Gilead Sciences Inc. reaps a windfall from its game-changing hepatitis C cure — largely thanks to payments from government programs — it garners a lower tax rate. That is not to say that Foster City-based Gilead (NASDAQ: GILD) is paying out less in taxes. Its provision for income taxes for the first half of this year was $1.4 billion, for example, or some $300 million more than it planned for all of 2013.